BRPI0816705A2 - Derivatido de 6-pirimidinil-pirimid-2-ona - Google Patents

Derivatido de 6-pirimidinil-pirimid-2-ona

Info

Publication number
BRPI0816705A2
BRPI0816705A2 BRPI0816705A BRPI0816705A2 BR PI0816705 A2 BRPI0816705 A2 BR PI0816705A2 BR PI0816705 A BRPI0816705 A BR PI0816705A BR PI0816705 A2 BRPI0816705 A2 BR PI0816705A2
Authority
BR
Brazil
Prior art keywords
pyrimid
ona
pyrimidinyl
derivative
ona derivative
Prior art date
Application number
Other languages
English (en)
Inventor
Kenji Fukunaga
Kazutoshi Watanabe
Pascal Barneoud
Jesus Benavides
Jeremy Pratt
Original Assignee
Mitsubishi Tanabe Pharma Corp
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08290028A external-priority patent/EP2078717A1/en
Application filed by Mitsubishi Tanabe Pharma Corp, Sanofi Aventis filed Critical Mitsubishi Tanabe Pharma Corp
Publication of BRPI0816705A2 publication Critical patent/BRPI0816705A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
BRPI0816705 2007-09-14 2008-09-12 Derivatido de 6-pirimidinil-pirimid-2-ona BRPI0816705A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007269485 2007-09-14
JP2007275713 2007-09-25
EP08290028A EP2078717A1 (en) 2008-01-11 2008-01-11 6-Pyrimidinyl-pyrimid-2-one derivative
PCT/JP2008/066936 WO2009035162A1 (en) 2007-09-14 2008-09-12 6-pyrimidinyl-pyrimid-2-one derivative

Publications (1)

Publication Number Publication Date
BRPI0816705A2 true BRPI0816705A2 (pt) 2015-03-17

Family

ID=39874051

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816705 BRPI0816705A2 (pt) 2007-09-14 2008-09-12 Derivatido de 6-pirimidinil-pirimid-2-ona

Country Status (15)

Country Link
US (2) US8198437B2 (pt)
EP (1) EP2193129B1 (pt)
JP (1) JP5249320B2 (pt)
KR (1) KR20100074182A (pt)
CN (1) CN101883770A (pt)
AR (1) AR068439A1 (pt)
AU (1) AU2008297817A1 (pt)
BR (1) BRPI0816705A2 (pt)
CA (1) CA2698819A1 (pt)
EA (1) EA201070367A1 (pt)
MX (1) MX2010002765A (pt)
NZ (1) NZ584277A (pt)
TW (1) TW200927134A (pt)
WO (1) WO2009035162A1 (pt)
ZA (1) ZA201002213B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
BRPI0816705A2 (pt) 2007-09-14 2015-03-17 Mitsubishi Tanabe Pharma Corp Derivatido de 6-pirimidinil-pirimid-2-ona
TW201043618A (en) 2009-03-10 2010-12-16 Sanofi Aventis Intermediate compound for synthesizing pharmaceutical agent and production method thereof
WO2011019090A1 (en) 2009-08-13 2011-02-17 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives used as tau protein kinase 1 inhibitors
JP5442852B2 (ja) * 2009-08-13 2014-03-12 田辺三菱製薬株式会社 タウプロテインキナーゼ１阻害剤としてのピリミドン誘導体
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3453706A1 (en) 2017-09-08 2019-03-13 Basf Se Pesticidal imidazole compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116460A1 (en) 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being
TWI265164B (en) * 2001-09-21 2006-11-01 Mitsubishi Pharma Corp 3-substituted-4-pyrimidone derivatives
PL368816A1 (en) * 2001-09-21 2005-04-04 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
TWI357408B (en) * 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives
AR050865A1 (es) * 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
KR20070057931A (ko) 2004-09-29 2007-06-07 미쯔비시 웰 파마 가부시키가이샤 타우 단백질 키나아제 1 저해제로서의6-(피리디닐)-4-피리미돈 유도체
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
AR064660A1 (es) * 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
BRPI0816705A2 (pt) 2007-09-14 2015-03-17 Mitsubishi Tanabe Pharma Corp Derivatido de 6-pirimidinil-pirimid-2-ona
AR076014A1 (es) 2009-04-02 2011-05-11 Sanofi Aventis Derivados de 3- (1,4) oxazepan -4-pirimidona

Also Published As

Publication number Publication date
EP2193129B1 (en) 2012-10-24
US8198437B2 (en) 2012-06-12
US20120252812A1 (en) 2012-10-04
MX2010002765A (es) 2010-05-19
AU2008297817A1 (en) 2009-03-19
US20110021773A1 (en) 2011-01-27
EA201070367A1 (ru) 2010-08-30
ZA201002213B (en) 2011-06-29
WO2009035162A1 (en) 2009-03-19
CN101883770A (zh) 2010-11-10
KR20100074182A (ko) 2010-07-01
JP2010538969A (ja) 2010-12-16
EP2193129A1 (en) 2010-06-09
NZ584277A (en) 2011-11-25
US8518939B2 (en) 2013-08-27
CA2698819A1 (en) 2009-03-19
JP5249320B2 (ja) 2013-07-31
TW200927134A (en) 2009-07-01
AR068439A1 (es) 2009-11-18

Similar Documents

Publication Publication Date Title
BRPI0813707A2 (pt) Derivados de pirimidinil-piridazinona
BRPI0820112A2 (pt) Derivados de isoxazol-piridina
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
BRPI0812155A2 (pt) derivados de espiroindolinona
BRPI0817935A2 (pt) Derivados de biarila
DK2209786T3 (da) Pyrimidinsubstituerede purinderivater
ATE542825T1 (de) Substituierte piperidino-dihydrothienopyrimidine
BRPI0821573A2 (pt) benzofuropirimidonas
BRPI0818380A2 (pt) Combinação de herbicida-protetor
ATE501136T1 (de) Imidazopyridinone
BRPI0812518A2 (pt) Derivados de indazolamida
BRPI0814236A2 (pt) Derivados de quinazolinamida
BRPI0813836A2 (pt) Derivados pirazólicos
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
ATE514696T1 (de) Diphenyl-dihydro-imidazopyridinone
BRPI0811451A2 (pt) Exopolissacarídeo
BRPI0814519A2 (pt) Organopolissiloxano
DK2152370T3 (da) Aryletherpyridazinonderivater
DK2190837T3 (da) 4-pyrimidinsulfamid-derivat
BRPI0812840A2 (pt) 2-imidazolinas
AT505058A3 (de) Türschliesssystem
BRPI0815547A2 (pt) Depsipeptídeos cícliocos
BRPI0814718A2 (pt) Derivados de isoxazol-imidazol
BRPI0812994A2 (pt) Microbiocidas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.